Predictive implications of decreased CA19‐9 at 8 weeks during nab‐paclitaxel plus gemcitabine for the induction of second‐line chemotherapy for patients with advanced pancreatic cancer

BACKGROUND: Second‐line (2L) chemotherapy after nab‐paclitaxel plus gemcitabine (AG) is important for improving the survival of patients with advanced pancreatic cancer (APC). However, many patients fail to receive 2L chemotherapy because of rapid disease progression. Therefore, early recognition of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Rep (Hoboken)
Hlavní autoři: Iede, Kiyotsugu, Yamada, Terumasa, Kato, Ryo, Ueda, Masami, Tsuda, Yujiro, Nakashima, Shinsuke, Ohta, Katsuya, Matsuyama, Jin, Ikenaga, Masakazu, Tominaga, Shusei
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941508/
https://ncbi.nlm.nih.gov/pubmed/32969199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cnr2.1289
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky